secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001493152-24-010014
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR
--------------------------------------------------------------------------------

- Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).
- Cash $1.1M at Dec 31, 2023; raised $6.8M from warrant exercises in Jan & Feb 2024.
- R&D expenses fell to $2.2M (Q4) and $7.6M (FY) from $6.4M and $19.8M.
- FDA granted Breakthrough Therapy designation for PF614-MPAR in January 2024.
- Phase 3 enrollment for PF614 expected H2 2024 after positive End-of-Phase 2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/0001493152-24-010014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer